A Randomized Trial of High-Dose Vitamin D2 in Relapsing-remitting Multiple Sclerosis
Authors:
- L GrimaldiLGL Grimaldi
- F BarkhofFBF Barkhof
- M BeelkeMBM Beelke
- J BurtonJBJ Burton
- T HolmoyTHT Holmoy
- R HuppertsRHR Hupperts
- J KillesteinJKJ Killestein
- P RieckmannPRP Rieckmann
- M SchluepMSM Schluep
- J SmoldersJSJ Smolders
- SOLAR Study GroupSOLAR Study Group
Open Access
- 13 March 2012
- journal article
- Published by Wolters Kluwer Health in Neurology
- Vol. 78 (11) , 840-841
Abstract
# {#article-title-2} Stein et al.1 compared high- vs low-dose vitamin D2 treatment in MS without benefit in the high-dose treatment group. Sunlight exposure and reduced vitamin D3 levels independently contribute to MS risk. The effect of sunlight exposure is supported by decreased signs of actinic skin damage found in MS patients compared to controls.2 It is difficult to determine which of these 2 environmental factors is of primary importance as higher levels of sunlight exposure will enhance vitamin D levels. The incidence of …Keywords
This publication has 5 references indexed in Scilit:
- Efficacy of vitamin D3 as add-on therapy in patients with relapsing–remitting multiple sclerosis receiving subcutaneous interferon beta-1a: A Phase II, multicenter, double-blind, randomized, placebo-controlled trialJournal of the Neurological Sciences, 2011
- A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosisNeurology, 2011
- Sun exposure and vitamin D are independent risk factors for CNS demyelinationNeurology, 2011
- Vitamin D status and effect of low-dose cholecalciferol and high-dose ergocalciferol supplementation in multiple sclerosisMultiple Sclerosis Journal, 2009
- Clinical trials of multiple sclerosis monitored with enhanced MRI: new sample size calculations based on large data setsJournal of Neurology, Neurosurgery & Psychiatry, 2001